Sept. 1, 2005 — The U.S. Food and Drug Administration (FDA) and Genentech, Inc., have warned healthcare professionals via letter of study data linking trastuzumab (Herceptin) therapy to a ...
HERCESSI(TM) becomes one of two trastuzumab biosimilars on preferred formulary placement, expanding patient access to more affordable HER2-targeted oncology therapies RALEIGH, N.C., Jan. 5, 2026 ...
* Says co has filed a lawsuit and a petition for provisional disposition order against Nippon Kayaku Co.,Ltd, demanding the suspension of manufacturing and distribution of the biosimilar of anti-HER2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results